Investor Relations

Company Overview

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.

MindMed trades on NASDAQ under the symbol MNMD and on the Canadian Cboe Exchange under the symbol MMED.

Stock Snapshot

IR Contacts

Headquarters

Mind Medicine (MindMed) Inc.
One World Trade Center
Suite 8500
New York, NY 10007
United States

Investor Relations

Chris Brinzey
ICR Westwicke
ir@mindmed.co

Transfer Agent

Computershare Investor Services
100 University Ave.
8th Floor, North Tower
Toronto, Ontario M5J2Y1
Canada
T: 1-800-564-6253 (toll free in Canada and US)
T: 514-982-7555 (international direct dial)
F: 1-888-453-0330